Background. Zinc supplementation of young children in lower-income countries reduces morbidity from diarrhea and pneumonia and all-cause mortality, but the most cost-effective approach for distributing zinc supplements is unknown.
Introduction
Zinc is an essential nutrient required for the normal structure and function of multiple proteins and cellular membranes that are involved in a broad array of metabolic and physiological processes, including DNA replication, immune system performance, and endocrine function. Zinc nutrition is particularly important during periods of rapid growth, such as pregnancy, early childhood, and adolescence. Zinc is critical for normal cellular replication, so rapidly renewing cells of the immune system and the gastrointestinal tract are particularly vulnerable to zinc deficiency. Exclusive breastfeeding seems to provide sufficient zinc intake for term infants under 6 months of age [1] . However, after about 6 months, children from low-income populations who subsist primarily on plant-derived food sources have an elevated risk of zinc deficiency because these foods have relatively low zinc contents and contain inhibitors of zinc absorption [2] .
Zinc deficiency during early childhood has multiple adverse consequences, including an increased risk of infectious diseases, such as diarrhea, pneumonia, and possibly malaria, as well as growth impairment. A recent systematic review conducted by the International Zinc Nutrition Consultative Group (IZiNCG) concluded that preventive zinc supplementation reduces the incidence of diarrhea by 27% among children 12 months of age or older, reduces the incidence of pneumonia by 15% to 21% overall (depending on the diagnostic criteria employed), and reduces all-cause mortality by 18% among children 12 months of age or older [3] . Some studies also suggest that zinc supplementation reduces the incidence of malaria [4] [5] [6] [7] , although the results are inconsistent [8] and there are still relatively few studies on this issue. Several meta-analyses have consistently demonstrated that zinc supplementation increases children's linear growth and weight gain, thereby reducing the risk of nutritional stunting and underweight [3, 9, 10] . Thus, improvements in zinc status can directly address Millennium Development Goals 1 (reduction of child underweight) and 4 (reduction of child morbidity and mortality).
In addition to these benefits of preventive zinc supplementation, multiple studies have shown that zinc supplements provided as adjunctive therapy for children with acute or persistent diarrhea significantly reduce the duration and, possibly, the severity of illness [11] . In particular, four systematic reviews have concluded that, when zinc supplements are provided during diarrhea, the duration of acute diarrhea is reduced by 7 to 12 hours (a reduction of 7% to 16%), and a smaller proportion of episodes persist for more than 8 days [11] [12] [13] [14] . Although this observed reduction in the duration of acute diarrhea has only minor clinical importance, two community-based intervention trials have also found a decrease in the overall incidence of diarrhea and a marginally significant reduction in the rate of acute lower respiratory tract infections in areas where zinc supplements were distributed for treatment of diarrhea [15, 16] . These sets of observations have motivated the World Health Organization (WHO) and UNICEF to launch a global effort to promote the inclusion of zinc in diarrhea treatment regimens, both because of the aforementioned advantages specifically provided by zinc therapy and to focus renewed attention on diarrhea treatment in general [17] . Although the WHO/UNICEF recommendation does not specify the age range of target children for therapeutic zinc supplementation, the three available studies of infants under 6 months of age failed to identify any beneficial impact of such supplements [14, 18] . Therefore, there currently seems to be little justification for initiating this intervention among children under 6 months of age.
Notably, an earlier pooled analysis of preventive zinc supplementation [19] reported that short-term therapeutic zinc supplementation given for acute [20] or persistent [21] diarrhea also reduced the incidence of subsequent episodes of diarrhea during the 1 to 2 months following the period of treatment. However, this pooled analysis was based on unpublished data, and when the full papers were subsequently published, they did not fully support these conclusions. In particular, the study of acute diarrhea only found a beneficial effect of zinc supplementation among malnourished children, and these results were confounded by the fact that the ages of zinc-treated and control malnourished children differed significantly [20] . The published paper on persistent diarrhea did not, in fact, show any differences in longer-term diarrhea risk between zinctreated and comparison children [21] . Thus, the longerterm effect of a brief period of zinc supplementation is still uncertain. If, indeed, there is a longer duration of benefit following short-term zinc supplementation, it is worth considering whether it might be more efficient to provide intermittent short-term preventive supplementation rather than wait for children to become ill with diarrhea before they can access these possible benefits of short-term supplemental zinc. Short-term preventive supplementation might have the further advantage of being compatible with delivery strategies designed to reach all children, not just those children whose caregivers seek treatment for diarrhea, which is a notoriously undertreated disease [22] [23] [24] . Thus, in the present analyses we also explore intermittent preventive supplementation as another option for preventing zincrelated infections and deaths, even though there is no existing programmatic experience with this approach.
In this paper we examine the potential impact of four possible strategies for delivering zinc supplementsdaily preventive zinc supplementation (DPZS), weekly preventive zinc supplementation (WPZS), intermittent short-term preventive zinc supplementation (IPZS), and therapeutic zinc supplementation as adjunctive treatment for episodes of diarrhea (TZSD)-on disease prevention and deaths averted among children from 6 months to 5 years of age in sub-Saharan Africa. The analytic approach that we will use is to quantify the potential impact of each of these different forms of supplementation on reducing episodes of diarrhea, pneumonia, and all-cause mortality, while assuming different target age ranges and different levels of program coverage; estimate the costs of these different delivery strategies and related delivery platforms, considering each of the assumptions regarding targeting and coverage; and calculate the benefits achieved for the various cost outlays. In all cases, the estimated costs of a public sector program will be the basis for these analyses, rather than private sector delivery strategies; costs to the household are not considered. The benefits will be measured in terms of years of life lost (YLLs) [25] ; other potential benefits with regard to morbidity reduction (and related savings for treatment costs avoided and prevention of lost parental employment) and improved nutritional status have not been considered in the analyses.
The challenge
There is very limited information on the global prevalence of zinc deficiency because most countries have not invested in direct assessment of their populations' zinc status [26] . However, an expert group convened by WHO, UNICEF, the International Atomic Energy Agency, and IZiNCG recommended that the prevalence of nutritional stunting (height-for-age less than -2 SD with respect to the international standard) among under-five children can be used as a proxy indicator of the risk of zinc deficiency [27] . According to estimates for sub-Saharan Africa, approximately 44.3 million children under 5 years of age (34.5% of that cohort's total population) had low height-for-age in 2005 [28] . Based on the prevalence of nutritional stunting and the amount of absorbable zinc in national food supplies, IZiNCG concluded that all 45 sub-Saharan African countries that were evaluated had an elevated risk of zinc deficiency [2] .
For the sake of the present analyses, we will assume that all countries in sub-Saharan Africa have an elevated risk of zinc deficiency, and that either all of the approximately 113 million children 6 to 59 months of age or all of the approximately 99 million children 12 to 59 months of age could have a beneficial response to zinc supplementation independently of their zinc status, depending on which outcome is being considered. This approach is justified because most zinc intervention trials enrolled unselected populations, not just stunted individuals, and, for the most part, the beneficial responses to zinc supplementation were not modified by preexisting child characteristics, including anthropometric status and serum zinc concentration [3] .
Approximately 35 million episodes of pneumonia [29] , 696 million episodes of diarrhea, and 4,480,000 deaths [24] occur among children under 5 years of age in sub-Saharan Africa per year. Pneumonia is responsible for around 1,022,000 deaths annually in sub-Saharan Africa [29] , or 23% of all under-five deaths in the region; diarrhea causes an additional 690,000 to 767,000 deaths [24, 30] , or 15% to 17% of all deaths.
Because zinc supplementation seems to affect diarrhea incidence and all-cause mortality only among children 12 months of age or older [3] , it is also important to know the age-specific incidence of these outcomes. According to recent reviews, the worldwide age-specific incidence of diarrhea for children 12 to 59 months of age is 2.3 episodes per child-year, and approximately 71% of all diarrhea episodes in under-five children occur among those who are 12 to 59 months of age [31, 32] . Assuming that these same age-specific proportions apply to sub-Saharan Africa, 492 million episodes of diarrhea and 515,050 diarrhea-related deaths occur among children aged 12 to 59 months (i.e., 71% of the total number of episodes of diarrhea and diarrhea-associated deaths among children under 5 years of age in sub-Saharan Africa). All-cause mortality among children 1 to 4 years of age represents 40% of all under-five mortality [24] . Thus, in sub-Saharan Africa, approximately 1,781,000 deaths occur each year among children 12 to 59 months of age.
Possible solutions
IZiNCG has proposed three major intervention strategies to control zinc deficiency: supplementation, fortification, and dietary modification [33] . However, studies of zinc delivery via point-of-use fortification products (micronutrient powders and lipid-based nutrient supplements), fortified processed complementary foods, and dietary modification interventions either have failed to demonstrate a significant impact on biochemical or functional indicators of zinc status or have not yet been conducted [34, 35] . Thus, until further evidence becomes available, zinc supplementation remains the only proven, efficacious intervention strategy.
As summarized above, two general approaches to zinc supplementation have been considered: preventive zinc supplementation, which is delivered routinely to children whether or not they are ill, and therapeutic zinc supplementation, which is delivered to children only in the context of disease treatment. Preventive zinc supplementation has generally been delivered on a daily basis in most intervention trials, although several studies have also found that weekly or twice-weekly zinc supplementation is efficacious for at least some functional responses [4, [36] [37] [38] . Notably, one study that compared daily versus weekly zinc supplementation in the same trial found that both dosing schedules reduced diarrhea incidence by 40% compared with the placebo group, and the responses to the two zinc interventions did not differ from each other [37] . Thus, it may not be necessary to deliver preventive zinc supplements every day to achieve the previously described reductions of morbidity and mortality. As discussed below, intermittent preventive supplementation might also be considered as a potentially effective alternative intervention strategy. Therapeutic zinc supplementation is currently recommended only for the treatment of diarrhea and severe malnutrition [17] .
Estimated impact of zinc supplementation programs on child deaths Estimated impact of daily and weekly preventive zinc supplementation
The recommended doses of DPZS vary according to age and frequency of administration, and the recommended daily dose for children 6 months to 5 years of age is 5 mg/day [2] . One dose-response study of daily supplementation with doses ranging from 3 to 10 mg zinc/day found that Ecuadorian children 12 to 35 months of age had reduced diarrhea incidence when they received as little as 3 mg zinc per day, although the greatest response was estimated to occur with a dose of approximately 6 mg zinc/day [39] . The amount of zinc that is absorbed from a single dose reaches a plateau as the dose is increased, and little additional absorption occurs when doses greater than 15 mg are provided to adults [40] . Moreover, higher doses are associated with more adverse effects, such as nausea and vomiting. Thus, it does not seem to be necessary or desirable to provide more than 10 mg per dose to young children who are not ill.
To estimate the likely impact of DPZS, we assumed initially that the supplements would be delivered to either 90% or 80% of the target population 6 to 59 months of age and that the supplements would reduce the incidence of pneumonia by 21% among children 6 to 59 months old, the incidence of diarrhea by 27% among children 12 to 59 months old, and all-cause mortality by 18% among children 12 to 59 months old (table 1), as was shown in the latest IZiNCG metaanalyses [3] . For the sake of comparison, we also examined the possible impact on mortality by applying the average case-fatality rates for diarrhea (0.3 %) [31] and pneumonia (1.95%) [41] to the number of cases averted to estimate the specific reduction in mortality due to diarrhea and pneumonia. We then repeated these analyses, applying the same assumptions for disease reduction, but restricting the age range of supplementation to children from 6 to 35 months of age. The purpose of the latter analyses was to assess the relative impact and cost-effectiveness if DPZS or WPZS were targeted just to children in this narrower age range. To estimate the percentage of deaths among children 12 to 59 months of age that occur among those who are 12 to 35 months of age, we used data from Demographic and Health Surveys (DHS) that suggest that approximately 67% of the deaths among 12-to 59-month-old children occur in the first 2 years of that age range [42] . In all cases, we assumed that the impact of DPZS and weekly preventive zinc supplementation (WPZS) would not differ, although this assumption remains to be confirmed by additional comparative studies. Although birth rates and life expectancy vary by country, for the purpose of the calculations of YLLs, we used the life expectancy at birth for all of sub-Saharan Africa (50 years) [24] and multiplied the number of deaths averted by the life expectancy minus the median age of children in the specific target age group.
As shown in table 1, if DPZS were provided to 90% of children 6 to 59 months of age, approximately 55 million cases of diarrhea (24% of all cases among children 12 to 59 months of age), 6 million cases of pneumonia (19% of all cases), and 289,000 deaths (16% of all deaths) would be averted. If deaths averted are estimated by assuming, instead, that the number of deaths averted is equal to the number of cases of diarrhea and pneumonia averted multiplied by the diarrhea and pneumonia case-fatality rates, respectively, the estimated number of deaths averted would be similar (approximately 287,000). These numbers of deaths averted equate to approximately 13.5 million YLLs gained. If 80% coverage of DPZS were achieved, the number of episodes of diarrhea, pneumonia, and deaths averted would be approximately 49 million, 5.5 million, and 257,000, respectively (assuming equal distribution of underlying risks in the subgroups covered or not covered), resulting in approximately 12 million YLLs gained. The table also provides estimates for diseases and deaths averted if the program targeted just children 6 to 35 months of age. As stated above, we assume the same number of disease outcomes averted for WPZS, although there is much less information available to support this assumption.
Estimated impact of therapeutic zinc supplementation
WHO and UNICEF recommend that children 6 months of age or older should receive 20 mg zinc per day for 10 to 14 days for treatment of episodes of diarrhea [17] . Most national programs seem to prefer 10 days of treatment, and evaluations of intervention programs show that, even when 14 days of supplements [24] and percentage of infant mortality that occurs among 6-to 11-month-olds (Ross and Burkhalter, unpublished). b. Deaths averted calculated based on 18% mortality in 12-to 59-month-olds and no impact on children under 12 months of age [3] . c. Deaths averted based on reduction of diarrhea (27%) and pneumonia (21%) [3] and the respective case-fatality rates for diarrhea (0.3%) [31] and pneumonia (1.29%) [41] . d. Calculation of YLLs based on life expectancy at birth of 50 years for sub-Saharan Africa [24] . are provided, the median number of tablets consumed is less than 10 [15, 16] . Thus, we conducted the present analyses assuming administration of 10 days of TZSD in relation to each treated episode of diarrhea.
There is relatively little information on the longerterm impact of TZSD, but one study in Bangladesh found a 15% reduction in diarrhea incidence and a (nonsignificant) 19% reduction in acute lower respiratory tract infection in communities where zinc supplements were provided in addition to oral rehydration solution (ORS) for diarrhea treatment, compared with communities that received only ORS [15] . Another study in India found a 25% reduction in diarrhea prevalence during the 24 hours prior to a cross-sectional survey in communities where diarrhea treatment regimens included TZSD, and a 63% reduction in caregiver-defined pneumonia [16] . Because of the limited information specific to these longer-term effects of TZSD, for the present analyses we assumed that the magnitude of protection against new cases of diarrhea, pneumonia, and death are the same as those observed with DPZS and that the duration of protection following each round of treatment is 2 months. It is also possible that TZSD reduces the case-fatality rate for the currently treated episode, but there are no relevant data currently available, and the small impact on diarrheal duration suggests that this impact, if present, would probably be small and possibly limited to deaths from persistent diarrhea. Because of the absence of specific information, we have not considered the possible effect of TZSD on mortality during the treated episode in the estimates of deaths averted by TZSD.
According to information currently available from a DHS for sub-Saharan Africa, only 32% of diarrhea episodes among children under 5 years of age are specifically treated with ORS or recommended home fluids, and around one-third of episodes are treated in a health center [24, 43] . These surveys are based on caregiver-defined diarrhea during the previous 2 weeks, so it is likely that the reported episodes represent more severe illnesses than are likely to be identified by more frequent community-based surveillance and using the WHO definition of diarrhea based on stool number and consistency [22, 44] . Thus, it is likely that the actual proportion of diarrhea cases treated outside the home is even less than the one-third reported from the DHS. Notably, the proportion of cases treated with ORS in the 68 UNICEF high-priority countries increased by only 2% during the period from 2000 to 2006 [45] , and very few episodes in sub-Saharan Africa are currently treated with zinc.
For the present analyses, we assumed that 90%, 80%, or 30% of episodes would be treated with TZSD. Children 6 to 59 months of age have an average of 2.6 episodes of diarrhea per year according to the WHO definition (three or more loose or liquid stools per 24 hours). Therefore, children would receive treatment for 2.3 episodes of diarrhea per year if 90% of episodes were treated, or 0.78 episodes per year if 30% were treated. However, the longer-term benefits of zinc would begin to accrue only after the first episode was treated, so this was taken into account in the analyses. If the age range of TZSD were restricted to children 6 to 35 months of age, the corresponding figures for average numbers of treated diarrhea episodes would be 3.0 or 1.0 episodes per year, respectively, if 90% or 30% of episodes were treated. For the present analyses, we assumed that diarrhea episodes were evenly distributed throughout the year. Table 2 provides estimates of the likely impact of TZSD. As indicated in the table, if 90% of diarrhea episodes occurring among children 6 to 59 months of age were treated with TZSD and the subsequent YLLs, years of life lost a. Population size per age range calculated based on population size and published mortality rates [24] and percentage of infant mortality that occurs among 6-to 11-month-olds (Ross and Burkhalter, unpublished). b. Deaths averted calculated based on 18% mortality in 12-to 59-month-olds and no impact on children under 12 months of age [3] . c. Deaths averted based on reduction of diarrhea (27%) and pneumonia (21%) [3] and the respective case-fatality rates for diarrhea (0.3%) [31] and pneumonia (1.29%) [41] . d. Calculation of YLLs based on life expectancy at birth of 50 years for sub-Saharan Africa [24] . protective benefit lasted for 2 months, then approximately 19 million future cases of diarrhea, 2.67 million future cases of pneumonia, and 110,000 deaths could be averted, which amounts to approximately 5.1 million YLLs gained. On the other extreme of the possible range of impacts, if only 30% of episodes were treated among children in this age range, and the duration of protection was 2 months after each round of treatment, the YLLs gained would be approximately 1.7 million.
Estimated impact of intermittent preventive zinc supplementation
IPZS has not yet been evaluated and is not currently practiced in large-scale programs, although there are several existing delivery platforms, such as child health days, growth monitoring and promotion, communitydirected treatment of parasites, and immunization programs, that offer potential opportunities for integrating this approach. In any case, if children who receive short-term zinc supplementation in the context of diarrhea treatment have a prolonged benefit of supplementation following the period of treatment, it seems reasonable to expect that children who are not ill who receive short-term supplementation would likewise enjoy a longer-term benefit. Thus, we have examined the potential impact and costs of delivering zinc supplements for 10 days once every 3 months. This would have a theoretical advantage over TZSD, because children would not have to become ill before they became eligible to receive the benefits of zinc supplementation. As with TZSD, we have assumed 2 months of protection following each round of IPZS. Thus, the protective benefit of IPZS would be two-thirds that of DPZS. As shown in table 3, if 90% of children 6 to 59 months of age received IPZS and the protection lasted 2 months, approximately 37 million cases of diarrhea, 4.1 million cases of pneumonia, and 192,000 deaths would be averted, resulting in approximately 9 million YLLs gained.
Estimated costs of zinc supplementation programs
Because there have been so few efforts to scale up zinc supplementation programs or monitor their costs, it is not possible to use existing program cost information. In a review of nutrition program financing, Horton et al. [46] described two possible approaches to estimating these costs when empirical information for specific programs is not available: using the likely costs of individual program components (e.g., costs of the supplements themselves; delivery costs and related expenditures for storage, transportation, staff salaries, training, and supervision; and costs of social mobilization campaigns), or using the actual costs of similarly designed programs that deliver other products.
Regrettably, there is little specific cost information available from other types of micronutrient supplementation programs, but relevant data that were cited in the aforementioned review included information from two studies of vitamin A supplementation delivered via child health days [47, 48] , one study of micronutrient powders [49] , and one study of zinc supplements provided with clinic-based diarrhea treatment [50] . These studies reported that the distribution costs of supplements during child health days ranged from US$0.60 to US$1.80 per child contact, although the figures from vitamin A distribution programs, which have considerably more experience, suggest that US$0.60 per child contact is a reasonable estimate. Although the marginal costs of adding new products to child health days are presumably less than the average cost of providing the current set of services and products, this relative savings might be partially offset by the greater number of zinc tablets required (and the higher related logistics costs). The study of TZSD reported that the delivery of zinc supplements during a diarrhea treatment contact increased the cost of the visit by US$0.50, of which US$0.20 was for the cost of 10 zinc tablets (US$0.02 each) and the rest was for the YLLs, years of life lost a. Population size per age range calculated based on population size and published mortality rates [24] and percentage of infant mortality that occurs among 6-to 11-month-olds (Ross and Burkhalter, unpublished). b. Deaths averted calculated based on 18% mortality in 12-to 59-month-olds and no impact on children under 12 months of age [3] . c. Deaths averted based on reduction of diarrhea (27%) and pneumonia (21%) [3] and the respective case-fatality rates for diarrhea (0.3%) [31] and pneumonia (1.29%) [41] . d. Calculation of YLLs based on life expectancy at birth of 50 years for sub-Saharan Africa [24] . additional staff counseling time and a related share of clinic infrastructure.
Zinc supplements could also be distributed through community nutrition programs or other communitybased service delivery activities, such as community-directed treatment with ivermectin (CDTI). Immunization contacts could also be used in some cases, but these do not cover the full age range required for zinc supplementation. The marginal cost of adding zinc supplements to existing community-based programs is difficult to estimate, so we assumed a fixed percentage increase in average program costs, based on the likely proportion of the total programmatic effort that would be required to include the distribution of zinc supplements, plus the cost of the zinc tablets. Horton et al. [46] estimated that community nutrition programs that deliver an array of services, such as breastfeeding promotion, counseling on complementary feeding, distribution of point-of-use fortificants, screening and referral for acute malnutrition, education on hand-washing, and distribution of maternal iron-folate tablets, incur an average cost of US$7.50 per child per year, although the number of child contacts was not specified. Because the interventions that they described included growth monitoring, we assume that this estimated annual cost represents 12 contacts per year, or US$0.62 per contact for the whole set of activities. Assuming that adding the distribution of zinc supplements to these community nutrition contacts might increase the overall program delivery costs by 10% to 20%, this would represent an additional cost of US$0.06 to US$0.12 per contact to include the distribution of zinc supplements. CDTI, which involves one contact per year, is estimated to cost US$0.15 per individual contact, exclusive of drug costs, although the cost per contact presumably would decrease with more contacts per year, because the training costs could be divided over a greater number of service delivery points [51] . Using these available figures, we estimated a range of US$0.06 to US$0.12 per contact through existing community-based delivery channels.
For the following analyses, we assumed that each dispersible zinc tablet provided in a blister package costs US$0.02, regardless of the zinc dose. Although it is likely that the cost per tablet would be less when more tablets are provided, we did not make any cost adjustments based on this possibility. The supplement delivery costs vary according to the delivery platform and the assumed level of coverage, as described above. For preventive zinc supplementation, we assumed that distribution would occur either at the time of semiannual child health days or via existing community nutrition programs or other community-based service delivery activities.
The above-noted delivery costs reported from existing programs were used for our estimates of the resources needed to achieve coverage up to 80%.
Because studies show that the marginal costs of achieving higher coverage are considerably greater [46, 52] , we assumed that the costs per child contact of reaching the last 10% of children required to reach 90% coverage would be twice the costs per child for reaching the first 80%.
Estimated costs of daily and weekly preventive zinc supplementation
To our knowledge, there are currently no large-scale programs that deliver preventive zinc supplementation to young children, so it is not possible to develop cost estimates based on existing empirical data. Using the limited available information from vitamin A supplementation programs during child health days, most of which deliver both vitamin A and antihelminth medication, we assumed that adding distribution of zinc supplements would increase the delivery costs by 50%, i.e., US$0.30 for each child contact during an already scheduled child health day. To these costs, we added US$0.02 for each zinc tablet provided (table 4) .
Using the foregoing assumptions, if 180 DPZS were provided during each of two semiannual child heath days, the annual cost of the program for children 6 to 59 months of age would be US$7.80 per child covered for the first 80% of children and US$8.40 per child covered for the remaining 10%, or a total cost of US$802 million to reach 90% of children in this age range in sub-Saharan Africa (table 4). The corresponding figure would be US$707 million if only 80% of children were reached. If the frequency of supplementation were reduced to weekly doses delivered through semiannual child health days, the total annual cost per child would be US$1.64 to reach 80% coverage, and the total cost of reaching 90% of children would be US$174 million.
We also estimated the cost of delivering DPZS through existing community nutrition programs. Assuming that the supplements would be distributed monthly with a delivery cost of either US$0.06 or US$0.12 per child contact, plus the cost of 360 supplements, the annual cost of the program to reach 80% of children 6 to 59 months in sub-Saharan Africa would be US$718 to US$783 million, depending on whether the lower or the higher estimate of distribution costs is applied. For a similarly designed program distributing WPZS, the total annual cost would be US$160 to US$225 million to reach 80% coverage (table 4).
Estimated cost of therapeutic zinc supplementation
Assuming that the additional cost of providing zinc supplements for each episode of diarrhea treated at a health clinic is US$0.50, as described above, the total annual cost of the program delivered to children 6 to 59 months would be approximately US$140 million if 90% of episodes were treated and approximately US$44 [46] . e. Additional costs for distribution of zinc tablets are assumed to be 20% of the total costs of community nutrition programs, which are estimated to be US$7.50/child/year [46] . f. Two additional child health days would need to be set up; for these US$0.60/child contact was assumed [48] .
million if 30% of episodes were treated (table 4) . The corresponding information for a program targeting just children 6 to 35 months of age is also shown in table 5.
Estimated cost of intermittent preventive zinc supplementation
We have estimated the costs of delivering IPZS in two ways: through quarterly child health days, two of which are already scheduled and two of which would need to be implemented just for IPZS; or via community nutrition programs. For the present analyses, we assumed that the costs of distributing zinc supplements during existing child health days would be as described above and the cost of the additional child contacts would be the same as for the existing child health days, i.e., US$0.60 per child contact to reach 80% coverage. According to the first set of assumptions, the annual costs of the program delivered to children 6 to 59 months of age would be approximately US$286 million if 90% of children were reached and approximately US$236 million if 80% of children were reached (table 4) .
Delivering IPZS through existing community nutrition programs to achieve 80% coverage of children 6 to 59 months of age would cost US$94 million according to the lower assumption for delivery costs and US$116 million according to the higher assumption. The relevant sets of information for targeting younger children only and for achieving higher coverage are shown in table 5. Table 5 summarizes total deaths averted per year, YLLs gained per year, average total annual program costs, and relative cost-effectiveness for each intervention strategy, assumed level of coverage, and supplement delivery costs, for children 6 to 59 or 6 to 35 months of age. As indicated in the table, the greatest impact on total lives saved can be achieved with daily or weekly preventive supplementation. Because of the assumed protective effect for 2 months following each round of IPZS, the total number of lives saved would be 66% of the number saved with the more frequent distribution strategies. As expected, more lives can be saved when the program targets all children 6 to 59 months of age rather than just those 6 to 35 months of age. Although TZSD can achieve nearly half the total impact of preventive supplementation when delivered at the same level of coverage, it seems very unlikely that such high levels of coverage could be achieved or sustained, because most episodes of diarrhea are fairly mild, and caregivers often fail to seek treatment for mild illnesses. Thus, 30% coverage might be a more realistic program target, and the impact achieved with this level of coverage might provide a more reasonable basis for comparison of intervention strategies.
Cost-effectiveness comparisons
The costs per life saved range from US$462 to US$3,111 for the different intervention strategies and related assumptions, and the costs per YLL range from US$10 to US$66. The total costs of the interventions are directly linked to the number of supplements provided and the number of contacts required to deliver these supplements. The percentage costs of the supplements themselves range from 31% to 92% of the total program costs. Because of the relatively high cost of procuring the supplements, DPZS costs more than WPZS, and WPZS costs slightly more than IPZS when both use the same delivery platform (i.e., community nutrition services). However, IPZS costs about twice as much as WPZS when both are delivered by child health days and according to our current assumptions. This is because we believe that it is unlikely that proper administration of quarterly IPZS could be assured through semiannual child contacts, so two additional delivery days were budgeted. Assuming a 2-month window of protection of IPZS delivered quarterly, the cost per life saved is US$1,379 and the cost per YLL is US$29 when 80% coverage is achieved through quarterly child health days. These costs are US$551 per death averted and US$12 per YLL when coverage is delivered through existing community nutrition programs (lower cost assumption), which is similar to the costs for WPZS. Although these cost-effectiveness analyses suggest a similar cost-effectiveness for IPZS and WPZS when they are delivered through community nutrition programs, adherence to these dosing regimens needs to be confirmed under program conditions. TZSD requires the lowest total financial outlay. However, when the program costs are related to the likely attainable impacts, a somewhat different picture emerges, because TZSD can avert only a relatively small proportion of total deaths, even when delivered at relatively high coverage, which, as stated above, seems more difficult to attain than through preventive programs. DPZS is the most expensive intervention, overall, but the costs of US$2,757 per life saved and US$59 per YLL gained that are associated with 80% coverage through child health days still make this a reasonably attractive intervention, which provides a large number of deaths averted. If WPZS can, indeed, provide the same number of deaths averted with the same level of coverage, it becomes an even more attractive intervention, because the cost per life saved is just US$580, and each YLL gained costs only US$12.
IPZS delivered through quarterly child health days costs about twice as much as TZSD to achieve the same level of coverage, but according to the assumptions applied in the current analyses, IPZS can save about twice as many lives, so the cost per life saved is nearly identical at US$1,195 to US$1,379 for 80% coverage. However, when IPZS is delivered through community [46] . d. Additional costs for distribution of zinc tablets are assumed to be 20% of the total costs of community nutrition programs, which are estimated to be US$7.50/child/year [46] . e. Two additional child health days would need to be set up; for these, US$0.60/child contact was assumed [48] . nutrition programs, it costs slightly less than TZSD, so the cost per life saved with IPZS would be less than half of that with TZSD. This comparison weighs even further in favor of IPZS when the likely lower coverage of diarrhea treatment interventions is taken into consideration. Thus, if both the number of deaths averted and cost-effectiveness are used as the major considerations for priority-setting, IPZS seems to be a more attractive alternative than TZSD, regardless of the assumed duration of protection.
Because a greater proportion of deaths among 12-to 59-month-old children occurs during the first 2 years of this age range, deaths can be averted at lower cost per life saved when the programs target children 6 to 35 months of age. Of course, a greater number of total deaths can be averted by focusing on the more extensive age range, thereby providing some difficult choices when prioritizing limited resources.
Limitations of the analyses
There are a number of caveats that must be recognized when reviewing the foregoing results. Most important among the limitations of this analysis is the fact that several of the interventions have not yet been tested at scale, so the true programmatic impacts and actual costs are uncertain. Moreover, there are a number of gaps in the background data that were used to generate the calculations presented. The most important shortcomings are described below, after which we present a brief description of some of the additional economic data that need to be collected as zinc supplementation programs are being implemented. We recognize that programs rarely achieve 90% coverage, but we used this hypothetical figure in the current analyses to estimate the maximum likely impacts and costs of the different intervention strategies.
Morbidity impact of different intervention strategies
There are a number of issues that need to be considered regarding the existing morbidity information. First of all, the information regarding the impact of zinc supplementation on pneumonia incidence is still somewhat limited, so it is not possible to ascertain whether the beneficial effects that have been consistently observed in the available studies are restricted to children 12 months of age or older, as seems to be the case for the prevention of diarrhea and all-cause mortality, or whether they occur over the full range of young children at risk for zinc deficiency (i.e., those 6 to 59 months of age). Moreover, the observed impact of zinc supplementation on the incidence of pneumonia in community trials depended on the rigor of the methods that were applied to diagnose acute lower respiratory tract infection in the field. We used the figure of 21% reduction of pneumonia, which is based on the more specific diagnostic criteria, assuming that the available information on the incidence of pneumonia was collected with a similar degree of rigor.
A second issue relates to the age-specific information on disease incidence and mortality. We were not able to find age-specific data for pneumonia, so a single incidence rate was applied for all ages. Surprisingly, there are few published summary data on age-specific mortality rates within the age ranges of 0 to 12 months and 12 to 59 months. However, we were able to find one comprehensive unpublished paper on age-specific infant mortality rates according to month of age* and another review of age-specific mortality rates of 1-to 4-year-old children according to year of age [42] , so these data were applied where appropriate.
Thirdly, following a closer examination of available information, it appears that the duration of protection from new episodes of illness following short-term (10 to 14 days) treatment of diarrhea is still uncertain. Thus, we applied estimates of 2 months of protection in our analyses for both the therapeutic and the intermittent preventive supplementation scheme, although these figures will need to be confirmed by future studies.
There are also some uncertainties regarding the appropriate population denominators to use in different analyses, because regional demographic data and disease incidence data are sometimes reported for all of Africa and sometimes are disaggregated for sub-Saharan Africa. Moreover, these figures are continuously changing over time. Although these factors may introduce some inaccuracy in the numbers of cases of disease and of disease averted, they would not bias the comparisons by intervention strategy. Finally, we were also unable to identify age-specific information on life expectancy for sub-Saharan Africa, so a single figure for life expectancy at birth was applied in all cases.
Uncertainties regarding program costs
The numerous uncertainties regarding the true costs of delivering zinc supplements are described above. The current cost estimates are based almost entirely on program experience with delivery platforms for other nutrients or medications. These estimates are based on the data available, but they fall short in several fundamental ways of providing complete confidence in our estimates of the financial resources needed to expand nutrition programs, as discussed by Horton et al. [46] and others. Firstly, although cost estimates based on "program experience" provide a very good point of departure for assessing the costs of existing supplementation programs, they generally do not take into consideration seasonal variability or more irregular * Ross JS, Burkhalter BR. When do infants die? Pooled analysis of DHS data from 67 countries. Unpublished. fluctuations in costs, for example, due to staff turnover. Also, because supplementation and other activities are usually "bundled" with other services provided by health programs, assessing the true marginal costs of additional activities is challenging. In an extensive review of the cost of micronutrient interventions, Fiedler et al. [53] found that the literature contains enormous variation in estimated costs of these programs. For example, the annual per person costs of vitamin A supplementation ranged from US$0.60 to US$29, with a mean of US$8.53 and a median of US$3.29. Although the programmatic costs of zinc supplementation may be higher than assumed in our analyses, our annual cost per person is close to the mean cost of vitamin A supplementation.
Secondly, and more importantly, although program experience-based cost estimates can be quite accurate for ongoing programs, there are good reasons to doubt that they provide an accurate assessment of the costs associated with dramatic expansions of interventions, especially those aiming to achieve near-universal coverage. The costs of expanding services are not likely to be uniform geographically. Hinterland areas are much more costly to serve than, say, urban or periurban areas, and these cost differences can be exacerbated during rainy seasons. Moreover, as discussed above, the unit costs of distribution may rise considerably as programs approach universal coverage. In addition, at some point the expansion of existing delivery platforms may exceed their ability to absorb new activities and logistical complexities. Thus, our assumption of doubling the cost to reach the remaining 10% of children needed to reach 90% coverage may be an underestimate of the true costs.
Finally, all of the foregoing analyses focus exclusively on supply-side issues. Demand-side issues, which depend on households' perceptions of the benefits of proposed interventions, as well as the benefits of alternative uses of household resources (perhaps most importantly household labor), and the constraints households face in achieving food and livelihood security, are not addressed. These have important implications for the costs of "social mobilization" or "behavior change" components of the micronutrient intervention programs. These and other shortcomings in the existing data should be addressed as we proceed to implement new nutrition interventions.
Unmeasured program benefits
Another important issue with regard to assessing the full range of potential impacts of zinc supplementation programs is the fact that current analyses did not address potential reductions in malaria incidence and growth restriction. Malaria was not considered, because the impact of zinc supplementation is still being debated [54] . Nevertheless, any impact of zinc supplementation on malaria-related deaths is presumably accounted for in the analyses of all-cause mortality. Thus, this is unlikely to change the cost per YLL substantially. Perhaps more importantly, the present analyses did not account for the known benefits of zinc for child growth, because these outcomes cannot easily be incorporated into YLLs. Nevertheless, zinc-induced improvements in growth address another Millennium Development Goal, providing further justification for confronting the problem of zinc deficiency apart from its impact on YLLs.
Finally, in addition to the obvious benefits of deaths averted, prevention of zinc-related disease will yield additional cost savings, both for health systems and for families of young children, by avoiding the need for treatment of a sizable number of cases of diarrhea, pneumonia, and acute malnutrition. These have not been considered in the present analyses.
Program implications of the analyses
These analyses support the earlier work of the Lancet series on maternal and child undernutrition and the Copenhagen Consensus Center, which concluded that control of zinc deficiency would be a key intervention for reducing child mortality at reasonably low cost [55, 56] . Although the present analyses are restricted to sub-Saharan Africa, the same general conclusions would presumably apply in other parts of the world with an elevated risk of zinc deficiency, such as South Asia and selected countries in Central and South America.
An important finding of these analyses is the potentially large impact of preventive zinc supplementation compared with zinc treatment of diarrhea, which has been the major programmatic thrust to date. Although improving diarrhea control programs, including the integration of adjunctive zinc therapy, is critically important to the child survival agenda, the current status of diarrhea control programs is clearly not adequate to make significant progress in controlling zinc deficiency and realizing the full potential for reducing zinc-related morbidity and mortality. These analyses underscore the compelling need to address zinc deficiency far beyond the constraints of diarrhea control programs.
Given the potential in lives saved and YLLs gained with improved zinc nutrition, and the fact that, to date, supplementation is the only proven efficacious intervention to improve zinc status, there is an urgent need to carry out program delivery and effectiveness research on preventive supplementation models that build on existing delivery platforms or that can be used for delivery of other child survival interventions. The analyses also demonstrate the important contribution of the zinc tablets, themselves, to total program costs. For this reason, an important research question will be to determine the minimum number of tablets required to achieve the recognized benefits of preventive zinc supplementation.
Ideally, delivery of zinc would be combined with delivery of other nutrients. In parallel with development of models for delivery of zinc supplements, research should continue to assess how to deliver zinc efficaciously through mass fortification programs, point-of-use fortificants, and fortified, processed complementary foods. Dose-response studies to determine the optimal amount of zinc to include in micronutrient powders, lipid-based nutrient supplements, and fortified foods are also needed. Interim program models that are developed for delivering zinc supplements could be adapted for delivery of other zinc-containing products as they are shown to be efficacious. However, in view of the large potential impact on children's morbidity and mortality, we do not need to wait for the availability of these future products to begin to deliver the known benefits of preventive zinc supplementation.
